Anticlastogenic effects of Aevitum intake in a group of chemical industry workers.
The incidence of chromosome aberrations (CAs) was investigated in cultured lymphocytes of 109 styrene-, formaldehyde-, and phenol-exposed workers in comparison with 64 controls. There was a marked increase in the incidence of the structural chromosome aberrations in the first mitotic division metaphases of occupationally exposed workers (3.59 +/- 0.26 CAs/100 cells vs 1.47 +/- 0.14 in controls (P < 0.01). 22 occupationally-exposed workers were selected for the trial including 1-month administration of a drug Aevitum (100,000 U of retinol palmitate plus 0.1 g of alpha-tocopherol acetate dissolved in 0.2 ml of oil) at a daily dose of 1-2 capsules for 5 days a week. The frequency of chromosome aberrations before, after the administration of a cumulative Aevitum dose of 2.0, 4.0 and 8.0 ml, and 6 weeks after the cessation of vitamin intake was 5.68 +/- 0.63, 4.33 +/- 0.45, 2.67 +/- 0.34, 2.00 +/- 0.25, and 2.64 +/- 0.21 per 100 cells, respectively. Thus, Aevitum was found to cause a significant decrease in occupationally-induced chromosome damage in human lymphocytes.
Ecological Genetics Laboratory, Vilnius University, Lithuania.
J
J
Mierauskiene
R
R
Lekevicius
J R
JR
Lazutka
D000293:Adolescent; D000328:Adult; D016587:Antimutagenic Agents / Q000494:pharmacology*; D002617:Chemical Industry; D002869:Chromosome Aberrations; D004338:Drug Combinations; D005260:Female; D005557:Formaldehyde / Q000009:adverse effects; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D016273:Occupational Exposure; D019800:Phenol; D010636:Phenols / Q000009:adverse effects; D020058:Styrene; D013343:Styrenes / Q000009:adverse effects; D014801:Vitamin A / Q000494:pharmacology*; D014810:Vitamin E / Q000494:pharmacology*
D016587:Antimutagenic Agents; D004338:Drug Combinations; D010636:Phenols; D013343:Styrenes; D014801:Vitamin A; D014810:Vitamin E; D005557:Formaldehyde; D019800:Phenol; D020058:Styrene; C048974:vitamin A, vitamin E drug combination